Cargando…

PD-L1 and intratumoral immune response in breast cancer

PURPOSE: PD-L1 is thought to play an important role in the antitumor immune response. In this study, we investigated the expression of PD-L1 within breast tumor subsets to better define its prognostic significance. METHODS: Immunohistochemistry was performed to determine PD-L1 tumor cell expression...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Zhi-Qiang, Milne, Katy, Derocher, Heather, Webb, John R., Nelson, Brad H., Watson, Peter H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5584276/ https://www.ncbi.nlm.nih.gov/pubmed/28881675 http://dx.doi.org/10.18632/oncotarget.18305

Ejemplares similares

CD74 and intratumoral immune response in breast cancer
por: Wang, Zhi-Qiang, et al.
Publicado: (2016)

Intratumoral Immune Responses Can Distinguish New Primary and True Recurrence Types of Ipsilateral Breast Tumor Recurrences (IBTR)
por: West, Nathan R., et al.
Publicado: (2011)

Tumor-infiltrating lymphocytes predict response to anthracycline-based chemotherapy in estrogen receptor-negative breast cancer
por: West, Nathan R, et al.
Publicado: (2011)

Location, location, location: CD103 demarcates intraepithelial, prognostically favorable CD8(+) tumor-infiltrating lymphocytes in ovarian cancer
por: Webb, John R, et al.
Publicado: (2014)

The Role of PD-L1 Expression and Intratumoral Lymphocytes in Response to Perioperative Chemotherapy for Urothelial Carcinoma
por: Erlmeier, F., et al.
Publicado: (2016)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Intratumor heterogeneity of PD-L1 expression in head and neck squamous cell carcinoma
por: Rasmussen, Jacob H., et al.
Publicado: (2019)

The peri- and intratumoral immune cell infiltrate and PD-L1 status in invasive squamous cell carcinomas of the penis
por: Müller, T., et al.
Publicado: (2021)

Intratumoral nanofluidic system enhanced tumor biodistribution of PD‐L1 antibody in triple‐negative breast cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Platelet PD-L1 reflects collective intratumoral PD-L1 expression and predicts immunotherapy response in non-small cell lung cancer
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Intratumoral characteristics of tumor and immune cells at baseline and on-treatment correlated with clinical responses to MPDL3280A, an engineered antibody against PD-L1
por: Kohrt, Holbrook, et al.
Publicado: (2013)

Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
por: Cloughesy, Timothy F., et al.
Publicado: (2019)

Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
por: Milne, Katy, et al.
Publicado: (2009)

Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway
por: Lv, Yipin, et al.
Publicado: (2019)

Correction: Systematic Analysis of Immune Infiltrates in High-Grade Serous Ovarian Cancer Reveals CD20, FoxP3 and TIA-1 as Positive Prognostic Factors
por: Milne, Katy, et al.
Publicado: (2013)

Metabolic rearrangements and intratumoral heterogeneity for immune response in hepatocellular carcinoma
por: Xu, Fei-Qi, et al.
Publicado: (2023)

Genetic dissection of intratumor heterogeneity of PD‐L1 expression in EGFR ‐mutated lung adenocarcinoma
por: Kunimasa, Kei, et al.
Publicado: (2023)

Immune response in breast cancer brain metastases and their microenvironment: the role of the PD-1/PD-L axis
por: Duchnowska, Renata, et al.
Publicado: (2016)

Tackling Immune Targets for Breast Cancer: Beyond PD-1/PD-L1 Axis
por: Tabana, Yasser, et al.
Publicado: (2021)

EBV(+) and MSI Gastric Cancers Harbor High PD-L1/PD-1 Expression and High CD8(+) Intratumoral Lymphocytes
por: De Rosa, Simona, et al.
Publicado: (2018)

Intratumoral Cytotoxic T-Lymphocyte Density and PD-L1 Expression Are Prognostic Biomarkers for Patients with Colorectal Cancer
por: Calik, Ilknur, et al.
Publicado: (2019)

Correction: Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway
Publicado: (2020)

Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma
por: Ran, Xia, et al.
Publicado: (2020)

Intratumor Heterogeneity in Hepatocellular Carcinoma: Challenges and Opportunities
por: Kalasekar, Sharanya Maanasi, et al.
Publicado: (2021)

Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
por: Roelands, Jessica, et al.
Publicado: (2020)

A Cross-Reactive Small Protein Binding Domain Provides a Model to Study Off-Tumor CAR-T Cell Toxicity
por: Hammill, Joanne A., et al.
Publicado: (2020)

Intratumoral expression levels of PD-L1, GZMA, and HLA-A along with oligoclonal T cell expansion associate with response to nivolumab in metastatic melanoma
por: Inoue, Hiroyuki, et al.
Publicado: (2016)

Tumour-infiltrating FOXP3(+) lymphocytes are associated with cytotoxic immune responses and good clinical outcome in oestrogen receptor-negative breast cancer
por: West, N R, et al.
Publicado: (2013)

The anticancer immune response of anti-PD-1/PD-L1 and the genetic determinants of response to anti-PD-1/PD-L1 antibodies in cancer patients
por: Sui, Xinbing, et al.
Publicado: (2015)

Measuring Intratumoral Heterogeneity of Immune Repertoires
por: Yuzhakova, Diana Vladimirovna, et al.
Publicado: (2020)

Intratumoral heterogeneity as a predictive biomarker in anti-PD-(L)1 therapies for non-small cell lung cancer
por: Fang, Wenfeng, et al.
Publicado: (2021)

Intratumoral T-cell and B-cell receptor architecture associates with distinct immune tumor microenvironment features and clinical outcomes of anti-PD-1/L1 immunotherapy
por: Schina, Aimilia, et al.
Publicado: (2023)

PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?
por: Xu-Monette, Zijun Y., et al.
Publicado: (2017)

Circulating and Intratumoral Adrenal Androgens Correlate with Response to Abiraterone in Men with Castration-Resistant Prostate Cancer
por: Mostaghel, Elahe A., et al.
Publicado: (2021)

CORRECTION NOTICE “Low intratumor heterogeneity correlates with increased response to PD-1 blockade in renal cell carcinoma”
Publicado: (2022)

Absolute lymphocyte count is associated with survival in ovarian cancer independent of tumor-infiltrating lymphocytes
por: Milne, Katy, et al.
Publicado: (2012)

Analysis of the Intratumoral Adaptive Immune Response in Well Differentiated and Dedifferentiated Retroperitoneal Liposarcoma
por: Tseng, William W., et al.
Publicado: (2015)

Correction: Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
Publicado: (2020)

Oncolytic virus expressing PD-1 inhibitors activates a collaborative intratumoral immune response to control tumor and synergizes with CTLA-4 or TIM-3 blockade
por: Ju, Fei, et al.
Publicado: (2022)

Immune checkpoint blockade in triple negative breast cancer influenced by B cells through myeloid-derived suppressor cells
por: Vito, Alyssa, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e1unae2qqdg5c9juhjeejlo6ls